ISSN: 0264-410X
Journal Home
Journal Guideline
Vaccine Q1 Unclaimed
Vaccine is a journal indexed in SJR in Infectious Diseases and Molecular Medicine with an H index of 175. It has a price of 2395 €. It has an SJR impact factor of 1,683 and it has a best quartile of Q1. It is published in English.
Type: Journal
Type of Copyright:
Languages: English
Open Access Policy: Open Choice
Type of publications:
Publication frecuency: -


2395 €
Gold OA-
Green OA0 €
Non OAMetrics
1,683
SJR Impact factor175
H Index1046
Total Docs (Last Year)3135
Total Docs (3 years)38978
Total Refs10094
Total Cites (3 years)2889
Citable Docs (3 years)3,37
Cites/Doc (2 years)37,26
Ref/DocAims and Scope
Other journals with similar parameters
The Lancet Infectious Diseases Q1
Clinical Microbiology Reviews Q1
Microbiology and Molecular Biology Reviews Q1
The Lancet HIV Q1
FEMS Microbiology Reviews Q1
Best articles
A look at new models to support vaccine research and development
View moreA model to estimate the potential economic benefits of measles eradication for the United States
View moreA possible explanation for the discrepancy between ELISA and neutralising antibodies to tetanus toxin
View moreAlkyl-polyacrylate esters are strong mucosal adjuvants
View moreAn editorial policy statement
View moreAnalysis of factors influencing vaccine uptake from various perspectives
View moreAnalysis of factors influencing vaccine uptake: perspective from Spain
View moreAnalysis of factors influencing vaccine uptake: perspectives from Belgium
View moreAnalysis of recombinant mouse zona pellucida protein 2 (ZP2) constructs for immunocontraception
View moreAnti-HBs characteristics after hepatitis B immunisation with plasma-derived and recombinant DNA-derived vaccines
View moreAntibody response to influenza immunization in two consecutive epidemic seasons in patients with renal diseases
View moreAntigen receptors and dendritic cells
View moreBenefit and risk of vaccination as seen by the general public and the media
View moreBooster vaccination with recombinant hepatitis B vaccine four years after priming with one single dose
View moreBusiness perspectives of a European vaccine manufacturer
View moreCHILD Profile: an immunization registry and more--a new approach to tracking and surveillance
View moreComparison of the safety and immunogenicity of the lyophilized Merieux seed and the World Health Organization working reference BCG vaccines in school-aged children in Senegal
View moreCost-effectiveness of hepatitis A and B vaccination programme in Germany
View moreDetection of adverse events: what are the current sensitivity limits during clinical development?
View moreDeveloping vaccines involving new technologies to ensure safety and timely licensure
View moreDevelopment of a transgenic mouse neurovirulence test for oral poliovirus vaccine: international collaborative study 1993-1999
View moreDNA pulsed macrophage-mediated cDNA expression library immunization in vaccine development
View moreEffectiveness of hepatitis A vaccine in a former frequently affected community: 9 years' followup after the Monroe field trial of VAQTA®
View moreEfficacy of Vi polysaccharide vaccine against strains of Salmonella typhi: reply
View more
Comments